Hepta

Executive Summary

Hepta is a preclinical-stage biotechnology company developing a next-generation liquid biopsy platform for chronic diseases, with an initial focus on metabolic dysfunction-associated steatohepatitis (MASH). By combining artificial intelligence with epigenetic analysis of cell-free DNA from a standard blood draw, the company aims to provide non-invasive, tissue-level insights into liver biology. This approach could enable earlier detection, treatment guidance, and monitoring of MASH in routine clinical practice, addressing a significant unmet need given the high prevalence and current reliance on invasive biopsies. Founded in 2021 and based in Cambridge, Massachusetts, Hepta operates in the AI/ML and diagnostics sectors. While the company has not disclosed funding or valuation, its platform has the potential to disrupt the MASH diagnostic market, which is expected to grow substantially as new therapies enter the market. The technology's success depends on validation in clinical studies and regulatory clearance, but the non-invasive nature and AI-driven interpretation offer a compelling value proposition compared to existing imaging and biopsy methods.

Upcoming Catalysts (preview)

• Q3 2026Publication of Proof-of-Concept Clinical Data in MASH60% success
• Q4 2026Series A Funding Round Announcement70% success
• Q1 2027FDA Breakthrough Device Designation for MASH Liquid Biopsy50% success